| Sep 5 |
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
|
| Sep 3 |
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
|
| Aug 26 |
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 19 |
Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
|
| Aug 16 |
Esperion Therapeutics: Strategically Positioned To Grow
|
| Aug 13 |
Q2 2024 Esperion Therapeutics Inc Earnings Call
|
| Aug 13 |
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
|
| Aug 12 |
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
|
| Aug 12 |
Esperion Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 12 |
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
|
